IOL Chemicals Posts ₹299.7 Million Profit In Q2 On ₹5.68 Billion Revenue

IOL Chemicals and Pharmaceuticals Ltd., a leading manufacturer of APIs and industrial chemicals, announced its Q2 FY26 financial results with consolidated revenue from operations at ₹5.68 billion and net profit of ₹299.7 million. The company’s results were driven by consistent demand for ibuprofen and other pharma intermediates, alongside disciplined cost management and export growth.

The performance highlights IOL’s strategic focus on product diversification and operational resilience in a competitive global market.

Key Highlights From The Earnings Report:  

• Revenue from operations stood at ₹5.68 billion, reflecting stable demand across domestic and international markets  
• Net profit reached ₹299.7 million, supported by margin expansion and improved working capital efficiency  
• The company maintained strong volumes in ibuprofen and specialty chemicals  
• Export orders remained robust, particularly in Europe, Latin America, and Southeast Asia  
• Management reaffirmed its focus on backward integration and capacity optimization  
• IOL continues to invest in green chemistry and compliance-driven manufacturing practices  
• The company is exploring new therapeutic segments and strategic partnerships for long-term growth

IOL Chemicals’ Q2 results underscore its strength in pharma and chemical manufacturing and its commitment to sustainable growth.

Sources: Reuters, BSE Corporate Filings, Economic Times Markets